Explore the latest in pancreatic cancer, including advances in understanding the epidemiology, diagnosis, management, and prevention of the disease.
This cohort study compares the outcomes of patients with BRCA1 and BRCA-related pancreatic cancers using 2 large data sets.
This case report describes a patient in their early 50s who presented with epigastric pain and jaundice and had significantly decreased heart rate after admission.
This randomized clinical trial compares short-term outcomes among patients undergoing laparoscopic vs open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
This cohort study investigates the prevalence of intraductal papillary mucinous neoplasms, their association with pancreatic cancer risk, and proportion with malignant transformation.
This multicenter diagnostic study assessed a prediction model that uses readily available blood biomarkers to possibly distinguish early-stage pancreatic cancer from benign periampullary diseases.
This case series assesses the gene-specific risk estimates of development of pancreatic ductal adenocarcinoma (PDAC) and extra-PDAC among first-degree relatives of patients with PDAC who carry pathogenic or likely pathogenic germline variants in cancer syndrome–associated genes.
This phase 3 randomized clinical trial examines the effect of broad-spectrum perioperative antimicrobial prophylaxis on postoperative surgical site infection incidence compared with standard care antibiotics (cefoxitin).
This cohort study evaluates the association between surgical resection and survival for patients with small, localized nonfunctional pancreatic neuroendocrine tumors.
This study attempts to evaluate how referral, treatment, and outcomes for patients with pancreatic adenocarcinoma vary by socioeconomic status and geography.
This cohort study of data from the National Cancer Database on patients with pancreatic adenocarcinoma who received neoadjuvant chemotherapy compares overall survival between those who received adjuvant chemotherapy and those who did not.
This randomized clinical trial investigates whether NPC-1C, an antibody directed against MUC5AC, might increase the efficacy of second-line gemcitabine and nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma (PDAC).
This phase 2b nonrandomized controlled trial evaluates whether the combination of avelumab and talazoparib is effective in patients with pathogenic BRCA1/2 or ATM alterations, regardless of tumor type.
This nonrandomized controlled trial assesses responses associated with the combination of avelumab and talazoparib in patients with different tumor types and molecular subtypes.
This cohort study evaluates survival outcomes with adjuvant chemotherapy for patients with node-negative disease after neoadjuvant therapy and surgical resection for pancreatic cancer.
This comparative effectiveness study evaluates long-term survival after minimally invasive and standard open surgery with curative intent among patients with pancreatic adenocarcinoma.
Customize your JAMA Network experience by selecting one or more topics from the list below.